研究单位：[1]Hoffmann-La Roche[2]The First Affilliated Hospital of Kunming Medical CollegeKunming,China,650032[3]The First People's Hospital of Yunnan ProvinceKunming,China,650032[4]Yunnan Cancer HospitalKunming,China,650118[5]The First Affiliated Hospital of Lanzhou UniversityLanzhou,China,730000[6]Gansu Cancer HospitalLanzhou,China,730050[7]Taizhou Hospital of Zhejiang ProvinceLinhai,China,317000[8]The First Affiliated Hospital of Henan UN of Science and TechnologyLuoyang,China,471003
研究目的：
This prospective, multi-center, non-interventional study will evaluate the efficacy and safety of trastuzumab in routine clinical practice in Chinese participants with gastric or gastro-oesophageal cancer. The study will be conducted in 5 cohorts and eligible participants will be enrolled and assigned to the various cohorts according to human epidermal growth factor receptor 2 (HER2) status, disease stage and treatment with trastuzumab according to physician's decision. Treatment patterns and clinical outcomes in participants with gastric cancer in China will be evaluated. The total study duration is 60 months.
